Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Istanbul University - Cerrahpasa30 enrolled

Overview

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Retinoblastoma

Interventions

intra-arterial administration of melphalanDRUG

Eligibility

Sex: ALLMin age: 5 MonthsMax age: 7 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients diagnosed with unilateral/bilateral retinoblastoma Exclusion Criteria: * patients with trilateral retinoblastoma * extraoculer involvement * patients with blood dyscrasias, bleeding and clotting disorders

Locations (1)

Istanbul University Cerrahpasa School of Medicine Ophthalmology Department

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

globe salvage

globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma

Time frame: 2-5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.